Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
Business Wire•26/10/2026•13:41 ET
1
Key Highlights
- ➤FDA expanded TALZENNA plus XTANDI approval to earlier HRR-mutated metastatic prostate cancer
- ➤TALZENNA plus XTANDI cut radiographic progression or death risk 52% versus control
- ➤Three-year progression-free rate estimated at 77% with TALZENNA plus XTANDI
- ➤Grade 3-or-higher anemia affected 51% of combination patients versus 3% control
- ➤EMA application remains under review, with additional global filings planned or underway
Expert Statements
Aamir Malik, Executive Vice President, Chief U.S. Commercial Officer, Pfizer
“Today’s approval of TALZENNA plus XTANDI builds on its established role as a standard-of-care option for men with advanced prostate cancer. Moving this targeted therapy into the androgen pathway modulation-naïve or -sensitive setting further reflects our commitment to men with HRR-mutated metastatic prostate cancer, providing a new option at a stage where it may have a greater impact to delay progression.”
Neeraj Agarwal, M.D., FASCO, Co-director of Prostate Cancer Program at Harvard Cancer Consortium, faculty medical oncologist at Dana-Farber Cancer Institute, and global lead investigator for TALAPRO-3
“This approval represents a critical advancement for patients with newly diagnosed metastatic prostate cancer with HRR gene mutations, who face a more aggressive disease, worse prognosis, and limited treatment options. In the TALAPRO-3 trial, clinical benefits were consistent for patients with BRCA and non-BRCA HRR gene mutations, addressing a long-standing unmet need – and reinforcing the importance of biomarker testing at the time of diagnosis.”
Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
TALZENNA plus XTANDI is now approved for HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, offering a potential new standard of care earlier in the course of disease
Get started
Create a free account to read the full story.